Background:Background: It is presently unknown which factors determine the occurrence and persistence of asthmaa in house dust mite allergic individuals. The level of allergen specific IgE antibodies does nott seem to be decisive for asthmatic symptoms. Moreover, levels of exposure to mite allergens doo not seem to differ significandy between asthmatic and non-asthmatics individuals. AimAim of this study: It was hypothesised that the presence or absence of asthmatic symptoms in housee dust mite allergic patients is associated with quantitative or qualitative differences in the cellularr bronchial inflammatory response during the late phase of the allergic reaction. This hypothesiss was tested in the bronchial allergen challenge model. MaterialMaterial and methods: Whole lung challenges with house dust mite extract were performed in 52 housee dust mite allergic subjects of whom 26 had asthma and 26 had perennial rhinitis without asthmaticc symptoms. Primary outcomes were parameters for bronchial inflammation in serial sampless of induced sputum (cell differentials, eosinophil cationic protein [ECP], Interleukin-8 [IL-8],, myeloperoxydase [MPO]). In addition, lung function, non-specific bronchial hyperresponsivenesss and serial blood samples (eosinophils and IL-5) were analysed. Results:Results: At baseline sputum eosinophils and ECP were similar in both groups but neutrophils and IL-88 were higher in asthmatics. The early bronchoconstriction after allergen challenge was similar inn asthma and non-asthmatic rhinitis (median decrease in FEV,: asthma -31.7% vs. nonasthmaticss -29.1%, p>0.1). The late phase bronchoconstriction was significandy greater in asthmaa (median decrease in FEV,: asthma -27.6% vs. non-asthmatics -18.9%, p=0.02). Inductionn of bronchial hyperresponsiveness was similar in both groups. Bronchial allergen challengee elicited significant increases in sputum eosinophils and ECP, which were indistinguishablee for both groups (p>0.1 and p=0.07, respectively). In contrast, higher numbers off neutrophils persisted in asthma 24 hrs after challenge and were accompanied by significant increasess in IL-8 and MPO, which were absent in non-asthmatics (difference between groups p^O.0077 and p=0.05, respectively).
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Introduction n
Subjectss allergic to common inhalant allergens are prone to develop symptoms of the upper airwayss as well as asthmatic symptoms. It remains to be established which factors determine the symptomaticc involvement of the lower airways in atopic individuals. Previous studies showed that thiss was not explained by differences in the level of allergen-specific IgE. Immediate allergic skin reactionss and early bronchial reactions appeared to be similar in rhinitics and asthmatics 1 " 3 . In addition,, there are no indications for persistent differences in exposure to environmental allergens 4 .. There is agreement in literature on the presence of some degree of eosinophilic bronchiall inflammation in non-asthmatic atopy 3 , but data on quantitative differences with bronchiall inflammation in asthma are inconclusive' . Patientss with allergic rhino-conjunctivitis show variable levels of non-specific bronchial hyperresponsivenesss but this is more pronounced in allergic asthmatics .
Inn spite of similar early asthmatic reactions (EAR), late asthmatic reactions (LAR) appear too be increased in asthmatics after inhalation provocation °. We hypothesised that quantitative or qualitativee differences in the late cellular bronchial inflammatory response after allergen exposure mightt be associated with the development or persistence of asthmatic symptoms. To test the hypothesiss we studied baseline bronchial inflammation and allergen induced changes in bronchial inflammationn after a standardised whole lung challenge as a model for the chronic bronchial inflammatoryy processes in allergic individuals.
Inn this prospective experimental study we investigated the late allergic inflammatory reactionn in the bronchi after challenge with house dust mite extract (HDM, D.pteronyssinus) in 522 HDM allergic individuals of whom 26 had asthma and 26 had perennial rhinitis without any evidencee for current or past asthmatic symptoms. Primary outcomes were bronchial influx of eosinophils,, neutrophils and changes in levels of eosinophil cationic protein (ECP), myeloperoxydasee (MPO) and interleukin-8 (IL-8) as detected in induced sputum 24 hours after a standardisedd early asthmatic reaction. Secondary outcomes were induction of bronchial hyperresponsiveness,, and changes in eosinophil counts and IL-5 levels in peripheral blood. The studyy was powered to detect a 25% difference in sputum eosinophils between groups. chapterr 5
Materialss and methods

StudyStudy subjects
Fifty-twoo subjects sensitised to HDM (D. Pteronyssinus) as determined by skin prick test (SPT) andd Radio Allergosorbent Test (RAST) were studied by the same investigator (CL). Asthma was diagnosedd according to the American Thoracic Society (ATS) criteria and included a documented historyy of recurrent episodes of wheezing, chest tightness and dyspnoea and a normal lung functionn between asthmatic attacks . Asthma severity before institution of treatment ranged from Gradee I (episodic) to Grade III (moderate persistent), according to the staging as proposed in the Globall Initiative for Asthma ". Rhino-conjunctivitis was not an exclusion criterion for the asthma group.. Non-asthmatic patients had perennial rhinitis characterised by recurrent sneezing, waterv rhinorrhoea,, pruritus in the nose, eyes and palate and nasal obstruction 13 . Patients with past or presentt asthmatic symptoms, a diagnosis of asthma and/or any previous use of bronchodilators weree excluded from the non-asthmatic perennial rhinitis group. The participating patients were recruitedd via the outpatient departments of Pulmonology and Otorhinolaryngology of the Academicc Medical Center.
Thee following inclusion criteria applied to all participants: a) FEV, > 70% of predicted value,, b) specific IgE to HDM > 0.5 kU/1, c) able to stop short acting ^-adrenoceptor agonists forr at least 8 hours, oral anti-histamines for 2 weeks and inhaled corticosteroids 6 weeks prior to thee start of the study, d) no significant change in environmental allergen exposure for one year (nott moved home, no allergen avoidance procedures), e) in the case of co-sensitisation against pollen,, patients participated in the study outside the relevant pollen season.
Exclusionn criteria were: a) history of immunotherapy, b) respiratory tract infection within 66 weeks prior to the study, c) other medication or comorbity, d) smoking. Thee study was approved by the local Medical Ethics Committee and all subjects gave written informedd consent. 
StudyStudy design
AA summary of the study design is shown in figure 1 . Prior to the inclusion all subjects were screenedd by RAST and skin prick test (SPT) with a standard panel of allergens and by spirometry. Corticosteroidss were withheld for 6 weeks. On the first day of the study period, duplicate skin prickk tests (SPT) with two-fold dilutions of the house dust mite extract (HDM) were performed andd blood samples were obtained. On the second day baseline sputum induction was performed followedd by PC 20 histamine, venepuncture and control bronchial challenge with diluent. On the thirdd day, bronchial allergen challenge was performed with a starting dose of allergen based upon thee skin test threshold and PC 2(l histamine according to the method described by Cockroft et al. ' 4 .
Patientss were observed for at least 8 hours and remained in the hospital if a late asthmatic reactionn with more than 20% decrease in FEV 3 persisted after 12 hours. On the next day and one weekk later sputum induction, PC 20 histamine and venepuncture were repeated.
AllergenAllergen extract AA single batch of a standardised house dust mite extract (1 mg dry weight/ml, equivalent to 10 6 SQQ units/ml and 50,000 BU/ml; ALK, Diephuis, Houten, The Netherlands) was used for all assays.. This extract contained 85.1 fig Der pi/mg protein and 9.7 ug Der p2/mg protein. It was keptt at -20°C. Allergen diludons were made freshly from stock in PBS with 0.03% human serum albuminn (HSA) and 0.5% phenol (ALK, Diephuis, Houten, The Netherlands) immediately before use. .
BronchialBronchial allergen challenge
Bronchiall allergen challenge was performed by using a reservoir aerosol deliver)-system as describedd previously x '. Shordy, a collapsible reservoir of approximately 30 litre, made of static fieldd dissipative material (RCAS 1206, Richmond Redknds, CA, USA) and filled with dry air, was connectedd to a highly efficient jet nebulizer (Mallinckrodt Diagnostica, Petten, The Netherlands) producingg an allergen aerosol from 0.5 ml allergen solution. The entire volume of the reservoir wass inhaled by tidal breathing through a 3-way valve system with the nose clipped. The day beforee to the bronchial allergen challenge, a control challenge was performed with 3 doses of diluentt (PBS, 0.03% HSA, 0.5% phenol) instead of allergen. The bronchial response to allergen 100 0 chapterr 5 expressedd as the percentage change from baseline FEV, was corrected for the diurnal variation in FEV,, as determined during the control challenge day.
BronchialBronchial histamine challenge
Bronchiall histamine challenge was performed 24 hours before, 24 hours after and 1 week after bronchiall allergen challenge according to the two-minute tidal breathing method described by Sterkk et al} 1 . Non-specific bronchial hyperresponsiveness was expressed as the concentration of histaminee diphosphate in PBS (range: 0.015 to 32 mg/ml) causing a 20% fall in FEV, (PC 20 histamine)) as calculated by log-linear interpolation.
SputumSputum induction
Sputumm induction was performed as described earlier . In short, hypertonic saline was nebulised byy an Aerodyne Omega Ultrasonic nebulizer (Kendall, Neustadt/Donau, Germany). The mass mediann aerodynamic diameter of the aerosol was 4.5 p.m. No sputum induction was performed whenn the FEV, was less than 80% of the baseline value or there were complaints of dyspnoea. Sputumm induction started with 3% saline inhalation for 15 minutes, thereafter the saline concentrationss were raised to 4% and 5% at 15 minutes intervals. Subjects were encouraged to expectoratee through several attempts of forced expiration following every inhalation interval. Sputumm was collected in plastic tubes and kept on ice until processing .
SputumSputum processing
Sputumm was processed according to the method described by Nocker et al. . An equal volume of dithiotreitoll (lOmM DTT in 135 mM Tris buffer, pH 8.0) was added to the sputum (DTT; Sigma Chemicall Company, St. Louis, Missouri, USA). The sample was incubated in a shaking bath of 37°CC for 15 minutes with periodically gendy manual mixing to ensure complete homogenisation. Celll numbers were counted in a Bürker counting chamber. Slides were stained with JennerGiemsaa staining and Romanovsky (Diff-Quick). Sputum samples that contained less than 20% non-squamouss cells or less than 50% viable cells were excluded from analysis. For cell differentialss a total number of 500 non-squamous cells were examined. If less than 2% eosinophilss was found another 500 non-squamous cells were counted in order to decrease the chapterr 5 101 1 confidencee limits of low eosinophil percentages. All differential cell counts were performed by onee investigator blinded for patient identity and sample time point.
ProteinProtein assays
Levelss of ECP were determined in the sputum supernatants with an ELISA described previously""--The detection limit was 15 pg/ml. Assay reagents (Rabbit-anti-human ECP antiserum andd anti-ECP antibody-biotin) were kindly donated by dr. A. Zuurbier (CLB Sanquin, Amsterdam,, The Netherlands). A standard dilution curve of ECP was derived from Pharmacia & Upjohnn (Uppsala, Sweden). Measurements of Der pi and Der fl in mattress dust were performed ass described before . MPO , IL-5", IL-8" and Alpha-2-macroglobulin (A2M)
1K
'~4 were measured byy ELISA as described earlier. Albumin was measured by an immunoturbidimetric assay with a Cobass Bio analyser (Roche, Diagnostics, Nutley, NJ, USA). As a standard "N protein" standard serumm for nephelometry was used (Behring, Marburg, Germany).
PeripheralPeripheral blood parameters
Venepuncturee was performed 24 hours before, 24 hours after and 7 days after inhalation of allergen.. Total and differential leukocyte counts were performed in EDTA-blood by using an automatedd fluorometric method (H 3 -RTX, Bayer-Technicon, Tarry town, NY). Filtered serum sampless were obtained after 1 hour of clotting on glass at room temperature and subsequent eenn tri fuga tion for 10 min at 1000 gfor detection ofIL-5.
Statisticall analysis
SPSS,, version 7.5.3 Statistics U.K. (Chicago, IL, USA) was used for statistical analyses. When applicable,, data were log-trans formed for parametric analyses. Data were summarised by (geometric)) mean and standard error (SE) or by median and interquartile range (IQR) in the absencee of a (log) normal distribution. Within group comparisons were analysed with paired t-test andd results verified with Wilcoxon test. Between groups comparisons were analysed with t-test andd verified with the Mann-Whitney test. Analysis was limited to the non-parametric tests when thee assumption that data arrived from a (log) normal distribution was rejected by KolmogorovSmirnovv and Shapiro-Wilk tests (serum 11-5, blood eosinophils, EAR and LAR). Comparison of allergenn induced changes in outcome parameters between groups was done with analysis of covariancee with post-challenge values as dependent variable, patient group as a fixed factor and baselinee values as covariate. Correlations were determined with the Spearman rank test. All pvaluess were two-tailed and p-levels of less than 0.05 were considered significant. Theree were no significant differences in gender, age and total IgE between asthmatics and nonasthmatics.. The majority of asthmatics (19/26) also appeared to have symptoms of perennial rhinitis.. Asthmatics had slightly higher levels of specific IgE to house dust mite. Since specific IgEE may contribute directly to the late allergic inflammation by antibody-facilitated antigen presentationn and subsequent activation of allergen-specific T lymphocytes and indirectly by its rolee in the immediate allergic reaction parametric analyses of primary outcomes were supplementedd by inclusion of specific IgE as a covariate. As expected, the level of non-specific bronchiall hyperresponsiveness was significantly higher in asthmatics. Baseline Forced Expiratory Volumee in one second (FEV,) expressed as percentage of predicted value was significantly lower inn the asthma group. Differences in lung function and non-specific bronchial hyperresponsivenesss persisted after adjustment for the level of specific IgE.
InflammatoryInflammatory parameters at baseline
Inn seventeen asthmatics and sixteen non-asthmatic rhinitics induced sputum was recovered successfullyy at baseline. The differences in eosinophil related parameters (percentage and total numberr of eosinophils and the level of ECP) in induced sputum did not reach significance (table  2) .. In contrast, the total number of neutrophils and the level of IL-8 were significantly higher in asthmatics.. Similar results were obtained when considering only the subgroup of non-asthmatics withh an EAR.
Inn peripheral blood no significant differences in baseline IL-5 and eosinophils were found betweenn both groups (median asthma IL-5-level 0. 
CorrelationsCorrelations between baseline bronchial inflammation, lungfunction parameters and symptoms
Overall,, baseline histamine thresholds showed a significant association with sputum ECP (R spearman:: -0.428, p=0.013), and sputum eosinophils (%eosinophils: Rs=-0.42, p=0.015 and numberr of eosinophils: Rs=-0.55, p=0.001), but not with other sputum parameters. By contrast, presencee and severity of asthmatic symptoms graded by the staging proposed in the Global Initiativee for Asthma (O-III) was associated with sputum IL-8 (Rs=0.35, p=0.046) and total neutrophilss (Rs=0.43, p=0.013) but not with other sputum parameters.
BronchialBronchial allergen challenge
Alll patients tolerated the allergen inhalation without complications. Short-acting beta-2-agonists forr relieve of symptoms were never used before 12 hours after challenge. Twenty-four hours after challengee none of the patients had airway symptoms and residual bronchoconstriction was less thann 15% decrease from baseline FEV, in all. However, some asthmatic patients had to restart maintenancee treatment for asthma in the first week after challenge because of exacerbation of symptoms. .
Alll asthma patients and twenty-one subjects of the non-asthmatic perennial rhinitis group experiencedd an early asthmatic reaction (EAR) defined by at least 20% fall in FEV,. In 5 nonasthmaticc patients early decrease in FEV, did not reach 20% with the highest dose of HDM deliveredd (2400 BU, drop in FEV, from baseline: range -6.5% to -19.5%). The maximal drop in FEV,, during the EAR was slightly but not significantly less in non-asthmatic patients as comparedd with asthmatics (median early decrease in FEV,: asthma -31. timee after final allergen dose
Figuree 2 Mean (SE) changes in lung function after bronchial allergen challenge in asthma and non-asthmaticc rhinitis. There is a significant difference during the phase of the Late Asthmatic Reactionn (LAR) between both groups after a similar Early Asthmatic Response (EAR).
chapterr 5
s\lkrgen-induceds\lkrgen-induced changes in bronchial inflammation
Twenty-fourr hours after allergen challenge induced sputum was successfully recovered from 16 asthmaticss and 17 non-asthmatics. Paired analysis of baseline and post challenge values demonstratedd significant increases in percentage eosinophils, number of eosinophils and ECP levelss in both groups (table 2) . However, neither the percentage and number of eosinophils at 24 hourss after challenge nor the change from baseline of eosinophils (table 2) differed significantly betweenn groups. The level of ECP was significantly higher in the asthma group at 24 hrs but the differencee did not reach statistical significance after correction for baseline values of sputum ECP. . Interestingly,, the differences in numbers of neutrophils and IL-8 level present at baseline betweenn both groups were even more pronounced 24 hours after challenge. Both IL-8 and MPO increasedd significandy in the asthma group but not in non-asthmatic rhinitis ( fig.3) . Analysis of thee 24 hr post challenge time point with correction for baseline levels confirmed that there was a significantt difference in the changes in the levels of IL-8 and MPO between asthma and nonasthmaticc rhinitics (table 2) . Adjustment for the difference in the levels of specific IgE to HDM didd not influence these results. Plasma protein leakage into the airway lumen as indicated by alpha-2-macroglobulinn and albumin in sputum, did not differ between asthma and nonasthmaticss at any of the time points. One week after challenge induced sputum was successfully recoveredd from 17 asthmatics and 15 non-asthmatic rhinitics. At this time point values had returnedd to baseline levels and no significant differences with baseline remained detectable in eitherr group. Between groups comparisons did not reveal significant differences. 
CorrelationsCorrelations between allergen-induced bronchial inflammation and lungfunction parameters
Bothh the degree of late phase bronchoconstriction and the increase in non-specific bronchial hyperresponsivenesss at 24 hour showed an association with the increase in sputum eosinophils (Rss = 0.50, p = 0.007 and Rs = 0.41, p = 0.03, respectively) but not with the change in other inflammatoryy markers in sputum. Multiple linear regression analysis was applied to predict the degreee of late phase bronchoconstriction by baseline non-specific bronchial hyperresponsiveness inn combination with changes in markers of inflammation in induced sputum. Besides baseline PC 2(l histamine,, the increase in sputum eosinophil counts at 24 hours appeared to be the only otherr independent variable to contribute significantly, (model R=0.75; standardized coefficients: chapterr 5
Allergen-inducedAllergen-induced changes in peripheral blood
Bothh serum IL-5 (median values before challenge and at 24 hours after challenge: asthma: 0.5 and 17.66 pg/ml, p<0.0001; non-asthmatics: 0.5 and 18.5 ng/ml, p<0.0001) and blood eosinophils (mediann values before challenge and at 24 hours: asthma: 240 and 405 10 6 /1, p<0.0001; nonasthmatics:: 195 and 345 10 6 /1, p<0.0001) showed a significant increase 24 hours after challenge butt without a statistical significant difference between groups. Increase in serum IL-5 was significantlyy associated with the increase in sputum eosinophils at 24 hours after challenge (Rss = 0.46, p = 0.015 for eosinophil numbers and Rs = 0.57, p = 0.002 for % eosinophils). No statisticallyy significant associations between changes in serum IL-5 and changes in peripheral bloodd eosinophils were found.
MouseMouse dust mite allergen in mattress dust
Thee mean levels of Der pi and Der f 1 as measured in mattress dust, which was sampled in a standardisedd way in all patients, did not differ between asthmatics and non-asthmatic rhinitics 
Discussion n
Inn this study on allergen induced bronchial inflammation in HDM allergic patients we found that thee difference between asthma and non-asthmatic rhinitis, in addition to the well-known functionall differences in non-specific bronchial hyperresponsiveness and FEV" appeared to be thee higher neutrophil counts and levels of IL-8 in induced sputum in asthma. After bronchial allergenn challenge with a standardised EAR the difference in neutrophil numbers found at baselinee persisted and was now accompanied by a significant increase in the level of IL-8 and MPOO in the asthma group only. Similar numbers of eosinophils and the eosinophil product ECP weree found at baseline and the significant increases in percentage and numbers of eosinophils afterr challenge were statistically indistinguishable for asthmatic and non-asthmatic patients. Thee majority of HDM allergic asthmatics also had symptom of perennial rhinitis which is inn keeping with literature 25 ' 26 . Actual natural exposure to HDM, as estimated from the concentrationn of Der p 1 and Der f 1 in mattress dust obtained from all patients, was found to be similarr in the asthma and the non-asthmatic rhinitis group. Thee validity of the classification as being asthmatic or non-asthmatic was affirmed by the significantt differences in baseline non-specific bronchial hyperresponsiveness and baseline FEV 1} parameterss that were not available for inclusion into either group. In accordance with literature non-specificc bronchial hyperresponsiveness was increased in the group of non-asthmatic patients withh allergic rhinitis although less so than in asthma 9 . The level of specific IgE to HDM was slightlyy higher in asthmatics, but the difference in spIgE may have been underestimated in this studyy because low spIgE (<0.5 KU/1) was applied as an exclusion criterion. Correction for the differencee in specific IgE by introducing it as a covariate in the statistical analysis did not change thee results of the primary outcomes.
We,, like others, reported that the level of non-specific bronchial hyperresponsiveness and thee level of specific IgE are the two main determinants of the allergen threshold for reaching an EAR 14, 16 .. Due to the higher degree of non-specific bronchial responsiveness as well as the higher levell of HDM specific IgE in asthma the dose of allergen administered in asthma was lower than inn non-asthmatic rhinitis. A possible difference in allergen induced influx of eosinophils into the airwayss in favour of asthma after similar allergen exposure may therefore have been obscured by chapterr 5 111 1 thiss phenomenon. For the same reason, the difference in IL-8, MPO, ECP and the number of neutrophilss after challenge, with higher levels in asthma in spite of lower allergen exposure, is likelyy to be underestimated in this study. Inn both groups induced sputum was successfully recovered in similar numbers of patients. Moreover,, comparison of patients who did or did not produce valid sputum did not reveal significantt differences in severity of complaints, lung function values or other indicators for diseasee severity. Therefore, bias of the study results based on a difference in the capability to producee induced sputum samples between the groups is unlikely. We, like others, found a significantt association between non-specific bronchial hyperresponsiveness at baseline and baselinee eosinophils and ECP in induced sputum. Interestingly, in this study presence of asthma symptomss appeared to be associated with neutrophil counts and the level of IL-8 in sputum and nott with eosinophils or ECP. The complete overlap in the extent of eosinophilic bronchial inflammationn in asthma and non-asthmatic perennial rhinitis at baseline as well as after allergen challengee suggests that other mechanisms in addition to eosinophilic bronchial inflammation may contributee to the development or persistence of asthmatic symptoms in allergic individuals.
Thee increased late asthmatic reactions after a similar early asthmatic reaction in asthmatics ass compared to non-asthmatic rhinitis confirms earlier reports 2 ' 3 ' 10 ' 2 . The finding that non-specific bronchiall hyperresponsiveness is the main determinant of the LAR independent of its contributionn to the EAR is also in accordance with earlier reports 28 . In addition to baseline nonspecificc bronchial hyperresponsiveness, the increase in eosinophil numbers in induced sputum but,, not of other markers of inflammation, was associated with the degree of the late phase bronchoconstrictionn and the increase in non-specific bronchial hyperresponsiveness. Late asthmaticc reactions were found both in asthmatics and in non-asthmatics although the frequency wass higher in asthma. Regarding the increased non-specific bronchial hyperresponsiveness at baselinee in asthma it is not surprising to find increased late phase bronchoconstriction in this groupp in spite of induction of a similar degree of eosinophilic bronchial inflammation. As contrastedd with changes in eosinophil numbers, neutrophil associated parameters did not show a statisticallyy significant association with the LAR. In accordance with other studies, we found that thee fold increase in percentage and numbers of eosinophils and the level of ECP was the main allergenn induced change in bronchial inflammation in asthma as well as in non-asthmatic rhinitis, butt there was no significant difference between patients with and without asthma. These results suggestt that late phase bronchoconstriction and to a lesser extent induction of non-specific bronchiall hyperresponsiveness induced by the allergen challenge procedure is similarly associated withh an increase in indices of eosinophilic inflammation in both groups, whereas the presence of clinicall asthma seems to be more closely associated with increased indices for neutrophilic inflammation.. This phenomenon may demonstrate one of the limitations of artificial allergen challengee as a model for chronic asthma. Thee difference in baseline neutrophil counts and IL-8 levels persisted after allergen challengee and was accompanied by a significant increase in the main neutrophil chemotactic interleukinn IL-8 and the neutrophil product MPO in asthmatics only. There may be various explanationss for the significant allergen-induced increases in IL-8 and MPO in asthmatics in the absencee of an increase in number of neutrophils as detected in the cell differentials. Increases in solublee markers may indicate a higher degree of neutrophil activation, but activation and subsequentt lysis of neutrophils may render cells unrecognisable in cell differentials and may lead too an underestimation of cell numbers. Alternatively, increases in soluble markers in the absence off increases in number of cells in sputum may point to selective accumulation of neutrophils in thee bronchial mucosa.
Inn contrast to baseline and 24 hours post challenge, the differences between asthma and non-asthmaticc rhinitis did not reach statistical significance one week after challenge. Possibly, restartingg of pulmonary medication in a number of asthma patients because of exacerbation of symptomss during the first week after allergen challenge may have contributed to this phenomenon. .
Takenn together these results suggest that neutrophilic bronchial inflammation may play an additionall pathophysiological role in bronchial inflammation in asthma. The results are compatiblee with the hypothesis that the combination of allergen induced eosinophilic inflammationn and an increased neutrophilic bronchial inflammation predisposes to the developmentt or persistence of asthmatic symptoms in allergic individuals. The implication of neutrophilss in the pathophysiology of severe asthma as reported in literature would be in keeping withh this vision""". The results are in line with our previous studies with segmental allergen challengee and sampling of bronchoalveolar lavage fluid at 4 hours after challenge, showing an chapterr 5enhancedd influx of neutrophils into the airway lumen in asthmatics as compared to allergic but non-asthmaticc controls . The maximal increase in airway eosinophils is reported to occur approximatelyy 24 hours after allergen challenge. In animal models influx of neutrophils after allergenn challenge precedes influx of eosinophils 32 . Therefore, studying bronchial inflammation 24 hourr after allergen challenge may have underestimated the contribution of neutrophils to the allergen-inducedd bronchial inflammation in asthma. Additional studies are necessary to investigate thee interaction between the eosinophilic and the neutrophilic component of the bronchial inflammation. .
Inn conclusion, the results of this study in house dust mite allergic patients suggest that neutrophilss contribute more to bronchial inflammation in allergic asthma than in non-asthmatic perenniall rhinitis and allergen challenge leads to increased levels of IL-8 and MPO in asthma only.. Presence of asthmatic symptoms does not seem to be determined by the number of eosinophilss present in the airways. Further studies into a contribution of neutrophils and their productss to the bronchial inflammation in asthma and the development or persistence of asthmaticc symptoms are warranted.
